Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lee’s Pharmaceutical Holdings Limited ( (HK:0950) ) has provided an update.
Lee’s Pharmaceutical Holdings Limited announced the approval of Socazolimab, an oncology drug developed by its subsidiary China Oncology Focus Limited, for marketing in combination with chemotherapy for the first-line treatment of extensive-stage small-cell lung cancer in Mainland China. The approval by the National Medical Products Administration is based on a successful Phase III clinical trial that demonstrated significant overall survival benefits without increasing safety risks. This development strengthens Lee’s Pharm’s position in the oncology market and underscores its commitment to advancing cancer treatment options.
More about Lee’s Pharmaceutical Holdings Limited
Lee’s Pharmaceutical Holdings Limited is a research-driven and market-oriented biopharmaceutical company with over 30 years of experience in the pharmaceutical industry in China. The company is fully integrated with capabilities in drug development, regulatory affairs, manufacturing, sales, and marketing, primarily based in Mainland China but with a global perspective. Lee’s Pharm focuses on key disease areas such as cardiovascular, women’s health, pediatrics, rare diseases, oncology, dermatology, and obstetrics, and has more than 20 products in various development stages. It has established extensive partnerships with over 20 international companies and markets over 25 proprietary, generic, and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau, and Taiwan.
Average Trading Volume: 470,210
Technical Sentiment Signal: Hold
Current Market Cap: HK$965.7M
Learn more about 0950 stock on TipRanks’ Stock Analysis page.